A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process

Biotechnology and Bioengineering

Volumn 104, Issue 3, 2009, Pages 492-504

  Streefland, M ^a   Van Herpen, P F G ^a   Van De Waterbeemd, B ^a   Van Der Pol, L A ^a   Beuvery, E C ^b   Tramper, J ^c   Martens, D E ^c   Toft, M ^d  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b PAT Consultancy ^*  (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d Umetrics AB   (Sweden)

Author keywords

Bordetella pertussis; Cultivation; DoE; PAT; Process analytical technology; Process design space; Process model

Indexed keywords

BORDETELLA PERTUSSIS; DOE; PAT; PROCESS ANALYTICAL TECHNOLOGY; PROCESS MODEL;

CELL MEMBRANES; CHEMICAL SENSORS; DESIGN; DRUG PRODUCTS PLANTS; INFRARED SPECTROSCOPY; LAWS AND LEGISLATION; METABOLITES; NEAR INFRARED SPECTROSCOPY; PROCESS MONITORING; SAFETY TESTING; SPECTROSCOPIC ANALYSIS; STATISTICS; VACCINES;

PROCESS DESIGN;

BACTERIAL VACCINE; PERTUSSIS VACCINE;

ARTICLE; DRUG MANUFACTURE; EXPERIMENTAL DESIGN; MONITORING; NEAR INFRARED SPECTROSCOPY; PERTUSSIS; PROCESS DESIGN; PROCESS MODEL;

BACTERIAL VACCINES; BORDETELLA PERTUSSIS; DRUG APPROVAL; TECHNOLOGY, PHARMACEUTICAL;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS;

EID: 70349322632     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22425     Document Type: Article

References (21)

1. Cummings CA, Bootsma HJ, Relman DA, Miller JF. 2006. Species- and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J Bacteriol 188(5):1775-1785.
2. FDA. 2004. Guidance for Industry, PAT - A framework for innovative pharmaceutical development, manufacturing and quality assurance. http://www.fda.gov/cder/guidance/6419fnl.pdf.
3. Harms J, Wang X, Kim T, Yang X, Rathore AS. 2008. Defining process design space for biotech products: Case study of Pichia pastoris fermentation. Biotechnol Prog 24(3):655-662. (Pubitemid 351832721)
4. ICH. 2005. Pharmaceutical Development (Q8). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use http://www.ich.org/LOB/media/MEDIA1707.pdf.
5. Irwin JO, Standfast AF. 1957. The intracerebral mouse-protection test for pertussis vaccines. J Hyg (Lond) 55(1):50-80.
6. Kasahara T, Miyazaki T, Nitta H, Ono A, Miyagishima T, Nagao T, Urushidani T. 2006. Evaluation of methods for duration of preservation of RNA quality in rat liver used for transcriptome analysis. J Toxicol Sci 31(5):509-519. (Pubitemid 46045158)
7. Kendrick PL, Eldering G, Dixon MK, Misner J. 1947. Mouse protection tests in the study of pertussis vaccine: A comparative series using the intracerebral route for challenge. Am J Public Health Nations Health 37(7):803-810.
8. Kourti T. 2006. Process analytical technology beyond real-time analyzers: The role of multivariate analysis. Crit Rev Anal Chem 36(3-4):257-278. (Pubitemid 44889531)
9. Lopes JA, Costa PF, Alves TP, Menezes JC. 2004. Chemometrics in bioprocess engineering: Process Analytical Technology (PAT) applications. Chemometr Intell Lab Syst 74(2):269-275. (Pubitemid 39488380)
10. Montgomery DC. 2001. Experimental design for product and process design and development. J R Statist Soc 48(2):159-177.
11. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE, Warrington JA. 2004. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 5(1):88. (Pubitemid 39546637)
12. Nomikos P, MacGregor JF. 1994. Monitoring batch processes using multiway principal component analysis. AIChE J 40(8):1361-1375.
13. Ramalho AS, Beck S, Farinha CM, Clarke LA, Heda GD, Steiner B, Sanz J, Gallati S, Amaral MD, Harris A. 2004. Methods for RNA extraction, cDNA preparation and analysis of CFTR transcripts. J Cyst Fibros 3(Suppl 2):11-15. (Pubitemid 40045558)
14. Streefland M, van de Waterbeemd B, Happe H, van der Pol LA, Beuvery EC, Tramper J, Martens DE. 2007. PAT for vaccines: The first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease. Vaccine 25(16):2994-3000. (Pubitemid 46482730)
15. Streefland M, van de Waterbeemd B, Kint J, van der Pol LA, Beuvery EC, Tramper J, Martens DE. 2008. Evaluation of a critical process parameter: Oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis. Biotechnol Bioeng 102(1):161-167.
16. Thalen M, van den IJssel J, Jiskoot W, Zomer B, Roholl P, de Gooijer C, Beuvery C, Tramper J. 1999. Rational medium design for Bordetella pertussis: Basic metabolism. J Biotechnol 75(2-3):147-159. (Pubitemid 29486614)
17. Van de Waterbeemd B, Streefland M, Pennings J, Van der Pol L, Beuvery C, Tramper J, Martens D. 2009. Gene-expression based quality scores indicate optimal harvest point in bacterial vaccine production. Biotechnol Bioeng 103(5):900-908.
18. Van Sprang ENM, Streefland M, Van der Pol LA, Beuvery EC, Ramaker HJ, Smilde AK. 2007. Manufacturing vaccines: An illustration of using PAT tools for controlling the cultivation of Bordetella pertussis. Qual Eng 19(4):373-384.
19. Wold S, Kettaneh N, Friden H, Homberg A. 1998. Modelling and diagnostics of batch processes and analogous kinetic experiments. Chemometr Intell Lab Syst 44(1-2):331-340. (Pubitemid 29016108)
20. Wold S, Kettaneh N, MacGregor J, Dunn K. 2008. Batch processes: Modelling, analysis and control. In: Walczak B, TaulerFerré R, Brown S, editors. Comprehensive chemometrics. Amsterdam, The Netherlands: Elsevier.
21. Xing D, Das RG, O'Neill T, Corbel M, Dellepiane N, Milstien J. 2001. Laboratory testing of whole cell pertussis vaccine: A WHO proficiency study using the Kendrick test. Vaccine 20(3-4):342-351. (Pubitemid 32973775)